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discovery are not effective enough. We have developed a bioin-
formatics pipeline to identify and classify all known viruses
present in a metagenomic sample. Viral NGS reads are identi-
fied using a protein-based alignment method, DIAMOND, which
is substantially faster than the standard BLAST method, and
more reliable for viruses. These reads are automatically
assembled into contigs using SPAdes, a de novo assembler. The
contigs are then used to classify the virus at species level using
a pan-viral typing tool based on all available taxonomic refer-
ence sequences from the International Committee on
Taxonomy of Viruses (ICTV) database. This bioinformatics pipe-
line is Java-encoded and will include an easy-to-use web inter-
face that is fit-for-purpose for researchers or clinicians. This
tool can assemble viral contigs from paired-end reads generated
by an Illumina MiSeq sequencer. So far 1865 viruses can be iden-
tified at species level resolution and 10 viruses (chikungunya
virus, dengue virus, HBV, HCV, HHV8, HIV-1, HPV, HTLV-1, YFV,
and Zika virus) at the genotype level. A web version of the pan-
viral typing tool is already available and a web version with
extended NGS functionality is currently being evaluated.
Eliminating the need for virus-specific laboratory techniques, or
targeted sequence capture, means a virome can be profiled in
the context of its non-viral microbiome. Preliminary findings
suggest our tool offers greater functionality than existing alter-
natives, with greater sensitivity to known viruses (including
bacteriophages), automatic assembly and good quality phyloge-
netic analyses. A systematic comparison is underway.
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The rate of HIV-1 disease progression varies widely between
individuals. This has been attributed to a combination of viro-
logical and immunological events during acute HIV infection
(AHI). However, the exact mechanisms explaining the relation-
ship between HIV-1 diversity, evolutionary dynamics and host
immune responses, and their effect on disease pathogenesis
remain unclear. We aim to dissect HIV-1 viral diversity, evolu-
tionary dynamics and select parts of the innate immune
responses observed during AHI, and elucidate virus-host mech-
anisms involved in the regulation of HIV-1 disease pathogenesis
during the acute and chronic stages of infection. A retrospective
longitudinal study design from well-characterized AHI cohorts
will be used. Archived samples from about 122 patients with
AHI (defined as HIV-1 antibody negative and RNA or p24 antigen
positive) from Europe (Sweden [n¼ 32]) and Africa (Kenya
[n¼ 32], Rwanda [n¼ 14], Uganda [n¼ 13], Zambia [n¼ 15], and
South Africa [n¼ 16]) will be included. Each patient will contrib-
ute plasma samples from four serial time points (<14, 30 [þ/
15], 90 [þ/ 30] and 360 [þ/ 180] days post estimated date of
infection, EDI) collected prior to treatment initiation. HIV-1 env
sequences determined by single genome sequencing (SGS), with
20 SGS clones from each time point, will be generated. In addi-
tion, a selected panel of innate immune markers will be profiled
using the Meso Scale Discovery (MSD) electro-chemilumines-
cence-based platform and/or ELISAs. A multi-dimensional
Bayesian framework of hierarchical phylogenetic models (HPM)
will be applied, allowing for both fixed and random effects prior
specifications to test for differences associated between and
within patient group parameters, and where all measured
virus-host parameters will be considered simultaneously. In
addition, evolutionary parameters in different stages of the dis-
ease i.e. acute and chronic phases, will also be measured and
accounted for in the HPM by addition of the epoch modeling
approach to quantify the relationships between viral parame-
ters, innate responses and their effect on disease pathogenesis.
The proposed study is likely to constitute one of the largest
virus-host dataset of longitudinally collected data of both virus
sequences (covering a wide range of HIV-1 subtypes) and innate
immune markers to date. The results of the proposed analyses
will increase our understanding of HIV-1 pathogenesis and may
have implications for therapeutic and prophylactic vaccine
design.
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In Slovenia, a small country in Central Europe, less than 1 per
1,000 inhabitants are estimated to be infected with HIV-1. As in
most of the Central and Western European countries, the
majority of patients diagnosed with HIV-1 are infected with sub-
type B. However, due to migration, other subtypes can become
more prevalent in the country. The aim of this study was to
determine HIV-1 subtypes circulating in Slovenia and to further
examine the molecular epidemiology of subtype A. A total of
367 Slovenian HIV-1 sequences were included in the study, rep-
resenting 58% of all patients diagnosed in Slovenia until the end
of the year 2013. Subtype was assigned by employing different
HIV subtyping tools coupled with Maximum likelihood phyloge-
netic analysis. The latter was performed to examine the molec-
ular epidemiology of subtype A as well. Identified clusters of
Slovenian subtype A sequences were further analyzed for the
determination of the time of the most recent common ancestor
(tMRCA) by using Monte Carlo Markov chain (MCMC) method
available in BEAST 2.1.3 software. We determined the preva-
lence of subtype B to be 85.3%, while subtype A was the most
prevalent non-B subtype found in 18 patients (4.9%), followed
by CRF02_AG (2.4%), subtype C (1.1%), subtypes D, G and
CRF01_AE (0.8% each) and subtypes F1 and CRF22_01A1 (0.3%
each). Subtypes could not be assigned to 12 sequences (3.3%).
The phylogenetic tree obtained by ML analysis of the subtype A
and subtype A related recombinants revealed that Slovenian
sequences were part of 6 major international clusters. Two clus-
ters consisting only of Slovenian sequences were identified and
thus additional MCMC analysis was employed. Results of a
Slovenian cluster of 4 subtype A sequences showed a posterior
probability value of 1 and a tMRCA between the years 1985 and
2008, with a mean in the year 2001. In conclusion, in a Central
21st International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology | S13
European country, where subtype B predominates, the second
most common subtype was found to be subtype A. Non-B sub-
types were observed in one out of seven patients in Slovenia, a
fraction that is not negligible, thus proving importance of sur-
veillance of HIV subtype diversity and corresponding molecular
epidemiology of non-B subtypes.
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Drug resistance is the main reason for antiretroviral treatment
(ART) failure. Information on the prevalence of pediatric HIV
drug resistance (HIVDR) in Vietnam is important to assist in the
determination of the optimal ART regimen. We enrolled a pro-
spective cohort of children newly initiating ART at one of two
main pediatric hospitals in Ho Chi Minh City from December
2011 to March 2014. Demographic and clinical data were col-
lected at baseline and supplemented by genotyping and VL at
start and after 12 months or when first-line ART ends if it comes
first. Of 136 patients enrolled, the mean age was 4.7 years; 17
(12%) exposed to ARV to prevent maternal to child HIV trans-
mission; seven (5.15%) carried at least one strain of HIV with
mutations related to ARV resistance, two (1.47%) against
Nucleotide Reverse Transcriptase Inhibitors (NRTIs) (AZT, D4T),
one (0.74%) against Non-Nucleotide Reverse Transcriptase
Inhibitors (NNRTIs) (NVP), and four (2.94%) against Nelfinavir of
Protease Inhibitors (PIs). At 12 months, 121 (89%) children were
still receiving the first line ART, 7 (5%) died and 8 (6%) were lost
to follow-up. Among 121 children on ART, 107(88%) achieved VL
suppression (<1,000 copies/mL); 9 (7%) had acquired HIVDR
mutations, three against NRTIs only, and six (4.96%) against
both NRTIs and NNRTIs. The most prevalent mutation was the
M184V (4.96%, n¼ 6) causing high-level resistance to 3TC, FTC
and low-level resistance to ddI and ABC. Some TAMs were also
found (D67N, K70R, T215F, K219Q). No major resistance muta-
tions to PIs were detected. Viral load at initiation is associated
with HIVDR at 12 months. Low levels of virologic failure and
HIVDR were observed in pediatric patients. However, since
some multidrug-resistant or cross-resistant mutations were
recorded, continued monitoring of HIV drug-resistance in pedia-
tric patients is needed.
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High levels of HIV envelope glycoprotein (Env) diversity have
been associated with the development of broadly neutralizing
antibodies (bNAbs). Here, we compare chronically HIV-1
infected subjects who develop bNAbs with those who did not, to
assess whether lack of breadth can be attributed to low levels of
viral diversity. Env nucleotide sequences were generated using
Single Genome Amplification from four CAPRISA 002 cohort
participants. Two participants developed neutralization breadth
(CAP256 and CAP257) whereas the other two did not (CAP88 and
CAP228) despite equivalently long duration of infection.
Longitudinal diversity analyses were performed using Sequence
Demarcation Tool (SDT). Phylogenetic analyses were performed
using Bayesian Evolutionary Analysis by Sampling Trees
(BEAST) software. Overall diversity increased with time in all
subjects, as expected. Highest diversity was observed in CAP256
and CAP228, followed by CAP257 and least diversity in CAP88.
The highest nucleotide substitution rates were observed in
CAP257 (2.63 substitutions/100 nucleotides/year), CAP256 (2.28
subs/100n/yr.) and CAP228 (2.07 subs/100n/yr.), and the lowest
in CAP088 (0.99 subs/100n/yr.). The time to the most recent
common ancestor (tMRCA) inferred from BEAST was longer
than the actual time of infection for CAP256 and CAP228, sug-
gesting the possibility of super-infection or multivariant infec-
tion. We conclude that the absence of viral diversity may limit
bNAb development, as in CAP88. However, increased diversity
through high mutation rates and/or recombination, while likely
necessary, is not sufficient for driving the development of
bNAbs.
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Common variants (>5% frequency) in the MHC and CCR5
regions are known to influence set point HIV-1 viral load (spVL)
yet explain only a portion of the total trait variance. The impact
of rare coding variation on HIV-1 disease progression has not
been as thoroughly investigated. Here we utilize exome
sequencing in 392 HIV-1 infected individuals with stable spVL
to look for rare and functional variants that mediate control of
HIV-1 infection. Set point HIV-1 viral load was calculated as the
average of at least 3 measurements obtained during the chronic
phase of infection. We captured and sequenced all coding exons
in 392 HIV-1 infected individuals of the Swiss HIV Cohort Study
using the Illumina Truseq 65Mb enrichment kit and the
Illumina HiSeq2000. Quality control and variant calling were
performed using the GATK and variant functional annotation
was performed using snpEff version 3.3. Individual variants
were tested for association using linear regression. Testing of
the combined effects of multiple low frequency variants across
each of >18,000 genes was performed using SCORE-Seq and
SKAT. Consistent with previous results, single marker variant
tests showed a strong signal of association in the MHC. The top
association was observed between spVL and rs1131446 (P¼ 2.3 
1011) in exon 3 of HLA-B. Conditioning on this SNP, residual
association was observed at rs2308622 (conditional P¼ 2.2 
106) in HLA-C. Accounting for these two SNPs, no other var-
iants showed evidence for association. Analyses aimed at
detecting the combined effect of multiple low-frequency var-
iants within a gene showed no significant associations.
Restricting this analysis to only those variants that result in a
change in protein sequence did not reveal further signals.
Outside of the MHC, no significant impact of rare variation on
spVL was detected by exome sequencing in 392 individuals.
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